Allogeneic hematopoietic cell transplantation for metastatic breast cancer

N. T. Ueno, J. D. Rizzo, T. Demirer, Y. C. Cheng, U. Hegenbart, M. J. Zhang, M. Bregni, A. Carella, D. Blaise, A. Bashey, J. D. Bitran, B. J. Bolwell, G. J. Elfenbein, K. K. Fields, C. O. Freytes, R. P. Gale, H. M. Lazarus, R. E. Champlin, P. J. Stiff, D. Niederwieser

Research output: Contribution to journalArticle

Abstract

We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC) regimens. More patients in the RIC group had poor pretransplant performance status (63 vs 26%, P=0.002). RIC group developed less chronic GVHD (8 vs 36% at 1 year, P=0.003). Treatment-related mortality rates were lower with RIC (7 vs 29% at 100 days, P=0.03). A total of 9 of 33 patients (27%) who underwent immune manipulation for persistent or progressive disease had disease control, suggesting a graft-vs-tumor (GVT) effect. Progression-free survival (PFS) at 1 year was 23% with myeloablative conditioning and 8% with RIC (P=0.09). Women who developed acute GVHD after an RIC regimen had lower risks of relapse or progression than those who did not (relative risk, 3.05: P=0.03), consistent with a GVT effect, but this did not affect PFS. These findings support the need for preclinical and clinical studies that facilitate targeted adoptive immunotherapy for breast cancer to explore the benefit of a GVT effect in breast cancer.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalBone Marrow Transplantation
Volume41
Issue number6
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Graft vs Tumor Effect
Cell Transplantation
Breast Neoplasms
Disease-Free Survival
Adoptive Immunotherapy
Survivors
Recurrence
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Ueno, N. T., Rizzo, J. D., Demirer, T., Cheng, Y. C., Hegenbart, U., Zhang, M. J., ... Niederwieser, D. (2008). Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplantation, 41(6), 537-545. https://doi.org/10.1038/sj.bmt.1705940

Allogeneic hematopoietic cell transplantation for metastatic breast cancer. / Ueno, N. T.; Rizzo, J. D.; Demirer, T.; Cheng, Y. C.; Hegenbart, U.; Zhang, M. J.; Bregni, M.; Carella, A.; Blaise, D.; Bashey, A.; Bitran, J. D.; Bolwell, B. J.; Elfenbein, G. J.; Fields, K. K.; Freytes, C. O.; Gale, R. P.; Lazarus, H. M.; Champlin, R. E.; Stiff, P. J.; Niederwieser, D.

In: Bone Marrow Transplantation, Vol. 41, No. 6, 03.2008, p. 537-545.

Research output: Contribution to journalArticle

Ueno, NT, Rizzo, JD, Demirer, T, Cheng, YC, Hegenbart, U, Zhang, MJ, Bregni, M, Carella, A, Blaise, D, Bashey, A, Bitran, JD, Bolwell, BJ, Elfenbein, GJ, Fields, KK, Freytes, CO, Gale, RP, Lazarus, HM, Champlin, RE, Stiff, PJ & Niederwieser, D 2008, 'Allogeneic hematopoietic cell transplantation for metastatic breast cancer', Bone Marrow Transplantation, vol. 41, no. 6, pp. 537-545. https://doi.org/10.1038/sj.bmt.1705940
Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplantation. 2008 Mar;41(6):537-545. https://doi.org/10.1038/sj.bmt.1705940
Ueno, N. T. ; Rizzo, J. D. ; Demirer, T. ; Cheng, Y. C. ; Hegenbart, U. ; Zhang, M. J. ; Bregni, M. ; Carella, A. ; Blaise, D. ; Bashey, A. ; Bitran, J. D. ; Bolwell, B. J. ; Elfenbein, G. J. ; Fields, K. K. ; Freytes, C. O. ; Gale, R. P. ; Lazarus, H. M. ; Champlin, R. E. ; Stiff, P. J. ; Niederwieser, D. / Allogeneic hematopoietic cell transplantation for metastatic breast cancer. In: Bone Marrow Transplantation. 2008 ; Vol. 41, No. 6. pp. 537-545.
@article{59a2d1df225a4c2e8b2273246b6b1dbd,
title = "Allogeneic hematopoietic cell transplantation for metastatic breast cancer",
abstract = "We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59{\%}) received myeloablative and 27 (41{\%}) reduced-intensity conditioning (RIC) regimens. More patients in the RIC group had poor pretransplant performance status (63 vs 26{\%}, P=0.002). RIC group developed less chronic GVHD (8 vs 36{\%} at 1 year, P=0.003). Treatment-related mortality rates were lower with RIC (7 vs 29{\%} at 100 days, P=0.03). A total of 9 of 33 patients (27{\%}) who underwent immune manipulation for persistent or progressive disease had disease control, suggesting a graft-vs-tumor (GVT) effect. Progression-free survival (PFS) at 1 year was 23{\%} with myeloablative conditioning and 8{\%} with RIC (P=0.09). Women who developed acute GVHD after an RIC regimen had lower risks of relapse or progression than those who did not (relative risk, 3.05: P=0.03), consistent with a GVT effect, but this did not affect PFS. These findings support the need for preclinical and clinical studies that facilitate targeted adoptive immunotherapy for breast cancer to explore the benefit of a GVT effect in breast cancer.",
author = "Ueno, {N. T.} and Rizzo, {J. D.} and T. Demirer and Cheng, {Y. C.} and U. Hegenbart and Zhang, {M. J.} and M. Bregni and A. Carella and D. Blaise and A. Bashey and Bitran, {J. D.} and Bolwell, {B. J.} and Elfenbein, {G. J.} and Fields, {K. K.} and Freytes, {C. O.} and Gale, {R. P.} and Lazarus, {H. M.} and Champlin, {R. E.} and Stiff, {P. J.} and D. Niederwieser",
year = "2008",
month = "3",
doi = "10.1038/sj.bmt.1705940",
language = "English",
volume = "41",
pages = "537--545",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for metastatic breast cancer

AU - Ueno, N. T.

AU - Rizzo, J. D.

AU - Demirer, T.

AU - Cheng, Y. C.

AU - Hegenbart, U.

AU - Zhang, M. J.

AU - Bregni, M.

AU - Carella, A.

AU - Blaise, D.

AU - Bashey, A.

AU - Bitran, J. D.

AU - Bolwell, B. J.

AU - Elfenbein, G. J.

AU - Fields, K. K.

AU - Freytes, C. O.

AU - Gale, R. P.

AU - Lazarus, H. M.

AU - Champlin, R. E.

AU - Stiff, P. J.

AU - Niederwieser, D.

PY - 2008/3

Y1 - 2008/3

N2 - We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC) regimens. More patients in the RIC group had poor pretransplant performance status (63 vs 26%, P=0.002). RIC group developed less chronic GVHD (8 vs 36% at 1 year, P=0.003). Treatment-related mortality rates were lower with RIC (7 vs 29% at 100 days, P=0.03). A total of 9 of 33 patients (27%) who underwent immune manipulation for persistent or progressive disease had disease control, suggesting a graft-vs-tumor (GVT) effect. Progression-free survival (PFS) at 1 year was 23% with myeloablative conditioning and 8% with RIC (P=0.09). Women who developed acute GVHD after an RIC regimen had lower risks of relapse or progression than those who did not (relative risk, 3.05: P=0.03), consistent with a GVT effect, but this did not affect PFS. These findings support the need for preclinical and clinical studies that facilitate targeted adoptive immunotherapy for breast cancer to explore the benefit of a GVT effect in breast cancer.

AB - We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC) regimens. More patients in the RIC group had poor pretransplant performance status (63 vs 26%, P=0.002). RIC group developed less chronic GVHD (8 vs 36% at 1 year, P=0.003). Treatment-related mortality rates were lower with RIC (7 vs 29% at 100 days, P=0.03). A total of 9 of 33 patients (27%) who underwent immune manipulation for persistent or progressive disease had disease control, suggesting a graft-vs-tumor (GVT) effect. Progression-free survival (PFS) at 1 year was 23% with myeloablative conditioning and 8% with RIC (P=0.09). Women who developed acute GVHD after an RIC regimen had lower risks of relapse or progression than those who did not (relative risk, 3.05: P=0.03), consistent with a GVT effect, but this did not affect PFS. These findings support the need for preclinical and clinical studies that facilitate targeted adoptive immunotherapy for breast cancer to explore the benefit of a GVT effect in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=41549095493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549095493&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705940

DO - 10.1038/sj.bmt.1705940

M3 - Article

C2 - 18084340

AN - SCOPUS:41549095493

VL - 41

SP - 537

EP - 545

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -